"Higher for Longer" Interest Rates: As a clinical-stage biotechnology company, CEL-SCI (CVM) is pre-revenue and heavily reliant on external funding for its research and development. Elevated interest rates increase the cost of capital, making it more expensive for the company to secure loans or attract equity investments, thereby impacting its operational runway and dilution risk.

Inflation (US Inflation at 3.3%): Rising inflation directly increases the operational costs for biotechnology companies, including expenses for clinical trials, manufacturing, and supply chains. This puts additional pressure on CVM's cash burn rate, potentially necessitating more frequent or larger capital raises which can lead to shareholder dilution.

Overall Investor Sentiment for High-Risk Assets Amid Geopolitical Instability: Global market conditions, including geopolitical tensions from the Iran War escalation and Strait of Hormuz closure, tend to shift investor sentiment away from high-risk, speculative assets like clinical-stage biotech stocks. This reduced appetite for risk can make it challenging for CVM to attract and retain investors, affecting its stock valuation and ability to fund future development.